Novogen Ltd (NVGN) 2.79 $NVGN
Novogen Lodges Key Super-benzopyran Patent
PR Newswire - Wed Feb 11, 9:00AM CST
Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced the lodgement of final specifications of a patent that covers the Company's first family of super-benzopyran compounds that to date has yielded leading drug candidates TRXE-002, TRXE-009 and TRXE-0025.
NVGN: 2.79 (+0.17)
Novogen to present at BIO & CEO Investor Conference 9th & 10th February, 2015
PR Newswire - Tue Feb 03, 9:00AM CST
Novogen Limited (ASX: NRT; NASDAQ: NVGN) is pleased to announce that Novogen Group CEO and Executive Chairman, Graham Kelly PhD, will be presenting at the 17th annual BIO CEO and Investor Conference being held on the 9th & 10th February, 2015.
NVGN: 2.79 (+0.17)
Novogen CEO to Present at Biotech and Money Conference in London
PR Newswire Europe - Fri Jan 23, 3:01AM CST
Novogen , an Australian-US drug discovery company focused on the development of novel therapeutics in the fields of oncology, degenerative disease and regenerative medicine, announced today that Graham Kelly, Ph.D., CEO and Executive Chairman, will present at the Biotech and Money London investor conference held during the 3(rd)-4(th) of February 2015.
NVGN: 2.79 (+0.17)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 16, 8:11AM CST
ATVI: 23.11 (+0.17), EOPN: 8.55 (-0.01), CS: 23.65 (+0.23), NVGN: 2.79 (+0.17), NBG: 1.61 (+0.18), FXCM: 2.21 (-0.01), RVP: 5.14 (-0.42), PCP: 205.54 (+1.37)
Recent Buzz on Street: New Research on BlackRock, Bank of America, Taiwan Semiconductor, Novogen and Kingtone Wirelessinfo
PR Newswire - Fri Jan 16, 7:20AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including BlackRock (NYSE: BLK), Bank of America (NYSE: BAC), Taiwan Semiconductor (NYSE: TSM), Novogen (NASDAQ: NVGN), and Kingtone Wirelessinfo (NASDAQ: KONE). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
BLK: 376.04 (+1.16), NVGN: 2.79 (+0.17), TSM: 24.84 (+0.37), BAC: 16.61 (-0.06), KONE: 4.20 (+0.03)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 15, 11:45AM CST
DRD: 2.27 (+0.10), OCN: 9.10 (+0.09), BBRY: 10.09 (+0.23), DCIX: 2.20 (+0.02), BBY: 39.11 (-0.08), RIC: 3.29 (-0.09), FISH: 22.86 (-0.24), NVGN: 2.79 (+0.17), SRNE: 11.41 (+0.56), WNS: 23.12 (+0.36), LPSN: 10.74 (+0.38), MUX: 1.10 (+0.06), ATNM: 3.60 (-0.29), PODD: 32.00 (-0.07), EDUC: 4.18 (-0.13), NGD: 3.73 (-0.04), PPC: 26.75 (+0.77), MOV: 25.26 (-0.17), KONE: 4.20 (+0.03), EHTH: 10.91 (-0.04)
Novagen jumps on announcement of regen med discovery
Seeking Alpha - at Seeking Alpha - Thu Jan 15, 9:31AM CST
NVGN: 2.79 (+0.17)
Novogen Announces Important Discovery in Regenerative Medicine Program
PR Newswire - Thu Jan 15, 9:00AM CST
Novogen Limited (ASX:NRT; NASDAQ:NVGN), an Australian/US biotechnology company, today announced an important discovery in its regenerative medicine program that has delivered a key proof-of-concept step forward in the quest to develop drugs capable of stimulating the function of brain tissue stem cells.
NVGN: 2.79 (+0.17)
Novogen to Conduct Shareholder/Investor Briefing in New York
PR Newswire - Wed Jan 07, 9:00AM CST
Novogen Limited (ASX:NRT; NASDAQ:NVGN), an Australian/US biotechnology company, today announced that it will hold a public Briefing for shareholders and investors in New York on 18th February 2015 at 2 pm New York time.
NVGN: 2.79 (+0.17)
Novagen to host investor presentation
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 6:10AM CST
NVGN: 2.79 (+0.17)
Notable Names In Securities Lending Last Week: NVGN, FRO
Interactive Brokers - at Seeking Alpha - Tue Jan 06, 1:35AM CST
As expected, trading activity was light last week given the market holiday and as many traders steered clear of the light volume characteristic of the final trading sessions of the year. Two names of note last week were Novogen Limited (NASDAQ: NVGN...
FRO: 2.96 (+0.07), GPRO: 45.27 (-0.02), HGSH: 3.05 (-0.13), NVGN: 2.79 (+0.17), CUBA: 8.68 (-0.13), JKS: 21.90 (+0.03), DO: 35.21 (+0.36), SCTY: 57.60 (+0.44), JCP: 8.05 (+0.14), CALA: 16.11 (+0.62), TRXC: 2.86 (-0.11), DGLY: 11.50 (-0.40)
Novogen expects another AUD1.75m from private placement to US Institutions
M2 - Mon Dec 22, 6:08AM CST
Biotechnology company Novogen (ASX:NRT)(NASDAQ:NVGN) said on Friday that it expects to raise gross proceeds of about AUD1.75m in a second private placement.
NVGN: 2.79 (+0.17), NRT: 14.11 (+0.31)
Novogen Raises An Additional A$1.75m in Private Placement to US Institutions for Aggregate Private Placement of A$5.85m
PR Newswire - Fri Dec 19, 9:00AM CST
Novogen Limited (ASX:NRT; NASDAQ:NVGN), Australian/US biotechnology company, today announced that it has entered into definitive agreements today to issue securities to existing institutional investors in the Unites States in a private placement with gross proceeds of approximately A$1.75 million. This private placement follows a private placement for gross proceeds of A$4.1 million that was previously announced on December 17, 2014. Aggregate gross proceeds from the two private placements are A$5.85 million. The closing of each private placement is expected to occur on or about 22 December 2014 and is subject to the satisfaction of customary closing conditions.
NVGN: 2.79 (+0.17)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 8:14AM CST
VIP: 5.37 (+0.51), TTPH: 35.18 (-0.73), FRO: 2.96 (+0.07), EXXI: 4.00 (+0.42), OVAS: 44.32 (+0.87), EOX: 1.15 (unch), NVGN: 2.79 (+0.17), WLT: 1.09 (+0.05), AKS: 4.87 (+0.39), MBT: 10.36 (+0.62), NADL: 2.10 (-0.02), NQ: 3.95 (-0.03), RVLT: 1.14 (-0.02), SSE: 5.23 (+0.22), AREX: 8.15 (+0.27), RAD: 8.34 (+0.25), AGEN: 5.03 (-0.01), PBR: 6.98 (+0.44), DNKN: 46.70 (-0.69), GDP: 3.58 (+0.29), SIMG: 7.25 (-0.01), KEG: 2.14 (+0.08), LINE: 12.94 (+0.40)
Novogen anticipates AUD4.1m from private placement
M2 - Thu Dec 18, 7:22AM CST
Biotechnology company Novogen (ASX:NRT)(NASDAQ:NVGN) said on Wednesday that it expects an aggregate gross proceeds of AUD4.1m from a private placement.
NVGN: 2.79 (+0.17), NRT: 14.11 (+0.31)
Novogen Raises A$4.1m In Private Placement to US Institutions
PR Newswire - Wed Dec 17, 9:00AM CST
Novogen Limited (ASX:NRT; NASDAQ:NVGN): Australian/US biotechnology company, Novogen Limited, today announced that it has entered into definitive agreements today to sell to institutional investors in the Unites States in a private placement for aggregate gross proceeds of approximately A$4.1M. The closing of the offering is expected to occur on or about 22 December 2014 and is subject to the satisfaction of customary closing conditions.
NVGN: 2.79 (+0.17)
Novogen Lodges Key Super-benzopyran Patent
PR Newswire - Wed Feb 11, 9:00AM CST
Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced the lodgement of final specifications of a patent that covers the Company's first family of super-benzopyran compounds that to date has yielded leading drug candidates TRXE-002, TRXE-009 and TRXE-0025.
NVGN: 2.79 (+0.17)
Novogen to present at BIO & CEO Investor Conference 9th & 10th February, 2015
PR Newswire - Tue Feb 03, 9:00AM CST
Novogen Limited (ASX: NRT; NASDAQ: NVGN) is pleased to announce that Novogen Group CEO and Executive Chairman, Graham Kelly PhD, will be presenting at the 17th annual BIO CEO and Investor Conference being held on the 9th & 10th February, 2015.
NVGN: 2.79 (+0.17)
Novogen CEO to Present at Biotech and Money Conference in London
PR Newswire Europe - Fri Jan 23, 3:01AM CST
Novogen , an Australian-US drug discovery company focused on the development of novel therapeutics in the fields of oncology, degenerative disease and regenerative medicine, announced today that Graham Kelly, Ph.D., CEO and Executive Chairman, will present at the Biotech and Money London investor conference held during the 3(rd)-4(th) of February 2015.
NVGN: 2.79 (+0.17)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 16, 8:11AM CST
ATVI: 23.11 (+0.17), EOPN: 8.55 (-0.01), CS: 23.65 (+0.23), NVGN: 2.79 (+0.17), NBG: 1.61 (+0.18), FXCM: 2.21 (-0.01), RVP: 5.14 (-0.42), PCP: 205.54 (+1.37)
Recent Buzz on Street: New Research on BlackRock, Bank of America, Taiwan Semiconductor, Novogen and Kingtone Wirelessinfo
PR Newswire - Fri Jan 16, 7:20AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including BlackRock (NYSE: BLK), Bank of America (NYSE: BAC), Taiwan Semiconductor (NYSE: TSM), Novogen (NASDAQ: NVGN), and Kingtone Wirelessinfo (NASDAQ: KONE). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
BLK: 376.04 (+1.16), NVGN: 2.79 (+0.17), TSM: 24.84 (+0.37), BAC: 16.61 (-0.06), KONE: 4.20 (+0.03)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 15, 11:45AM CST
DRD: 2.27 (+0.10), OCN: 9.10 (+0.09), BBRY: 10.09 (+0.23), DCIX: 2.20 (+0.02), BBY: 39.11 (-0.08), RIC: 3.29 (-0.09), FISH: 22.86 (-0.24), NVGN: 2.79 (+0.17), SRNE: 11.41 (+0.56), WNS: 23.12 (+0.36), LPSN: 10.74 (+0.38), MUX: 1.10 (+0.06), ATNM: 3.60 (-0.29), PODD: 32.00 (-0.07), EDUC: 4.18 (-0.13), NGD: 3.73 (-0.04), PPC: 26.75 (+0.77), MOV: 25.26 (-0.17), KONE: 4.20 (+0.03), EHTH: 10.91 (-0.04)
Novagen jumps on announcement of regen med discovery
Seeking Alpha - at Seeking Alpha - Thu Jan 15, 9:31AM CST
NVGN: 2.79 (+0.17)
Novogen Announces Important Discovery in Regenerative Medicine Program
PR Newswire - Thu Jan 15, 9:00AM CST
Novogen Limited (ASX:NRT; NASDAQ:NVGN), an Australian/US biotechnology company, today announced an important discovery in its regenerative medicine program that has delivered a key proof-of-concept step forward in the quest to develop drugs capable of stimulating the function of brain tissue stem cells.
NVGN: 2.79 (+0.17)
Novogen to Conduct Shareholder/Investor Briefing in New York
PR Newswire - Wed Jan 07, 9:00AM CST
Novogen Limited (ASX:NRT; NASDAQ:NVGN), an Australian/US biotechnology company, today announced that it will hold a public Briefing for shareholders and investors in New York on 18th February 2015 at 2 pm New York time.
NVGN: 2.79 (+0.17)
Novagen to host investor presentation
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 6:10AM CST
NVGN: 2.79 (+0.17)
Notable Names In Securities Lending Last Week: NVGN, FRO
Interactive Brokers - at Seeking Alpha - Tue Jan 06, 1:35AM CST
As expected, trading activity was light last week given the market holiday and as many traders steered clear of the light volume characteristic of the final trading sessions of the year. Two names of note last week were Novogen Limited (NASDAQ: NVGN...
FRO: 2.96 (+0.07), GPRO: 45.27 (-0.02), HGSH: 3.05 (-0.13), NVGN: 2.79 (+0.17), CUBA: 8.68 (-0.13), JKS: 21.90 (+0.03), DO: 35.21 (+0.36), SCTY: 57.60 (+0.44), JCP: 8.05 (+0.14), CALA: 16.11 (+0.62), TRXC: 2.86 (-0.11), DGLY: 11.50 (-0.40)
Novogen expects another AUD1.75m from private placement to US Institutions
M2 - Mon Dec 22, 6:08AM CST
Biotechnology company Novogen (ASX:NRT)(NASDAQ:NVGN) said on Friday that it expects to raise gross proceeds of about AUD1.75m in a second private placement.
NVGN: 2.79 (+0.17), NRT: 14.11 (+0.31)
Novogen Raises An Additional A$1.75m in Private Placement to US Institutions for Aggregate Private Placement of A$5.85m
PR Newswire - Fri Dec 19, 9:00AM CST
Novogen Limited (ASX:NRT; NASDAQ:NVGN), Australian/US biotechnology company, today announced that it has entered into definitive agreements today to issue securities to existing institutional investors in the Unites States in a private placement with gross proceeds of approximately A$1.75 million. This private placement follows a private placement for gross proceeds of A$4.1 million that was previously announced on December 17, 2014. Aggregate gross proceeds from the two private placements are A$5.85 million. The closing of each private placement is expected to occur on or about 22 December 2014 and is subject to the satisfaction of customary closing conditions.
NVGN: 2.79 (+0.17)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 8:14AM CST
VIP: 5.37 (+0.51), TTPH: 35.18 (-0.73), FRO: 2.96 (+0.07), EXXI: 4.00 (+0.42), OVAS: 44.32 (+0.87), EOX: 1.15 (unch), NVGN: 2.79 (+0.17), WLT: 1.09 (+0.05), AKS: 4.87 (+0.39), MBT: 10.36 (+0.62), NADL: 2.10 (-0.02), NQ: 3.95 (-0.03), RVLT: 1.14 (-0.02), SSE: 5.23 (+0.22), AREX: 8.15 (+0.27), RAD: 8.34 (+0.25), AGEN: 5.03 (-0.01), PBR: 6.98 (+0.44), DNKN: 46.70 (-0.69), GDP: 3.58 (+0.29), SIMG: 7.25 (-0.01), KEG: 2.14 (+0.08), LINE: 12.94 (+0.40)
Novogen anticipates AUD4.1m from private placement
M2 - Thu Dec 18, 7:22AM CST
Biotechnology company Novogen (ASX:NRT)(NASDAQ:NVGN) said on Wednesday that it expects an aggregate gross proceeds of AUD4.1m from a private placement.
NVGN: 2.79 (+0.17), NRT: 14.11 (+0.31)
Novogen Raises A$4.1m In Private Placement to US Institutions
PR Newswire - Wed Dec 17, 9:00AM CST
Novogen Limited (ASX:NRT; NASDAQ:NVGN): Australian/US biotechnology company, Novogen Limited, today announced that it has entered into definitive agreements today to sell to institutional investors in the Unites States in a private placement for aggregate gross proceeds of approximately A$4.1M. The closing of the offering is expected to occur on or about 22 December 2014 and is subject to the satisfaction of customary closing conditions.
NVGN: 2.79 (+0.17)
